323 related articles for article (PubMed ID: 15946143)
1. Cytokeratin immunoreactivity patterns in short-segment Barrett's esophagus in Japanese patients.
Yagi K; Nakamura A; Sekine A
J Gastroenterol Hepatol; 2005 Jun; 20(6):929-34. PubMed ID: 15946143
[TBL] [Abstract][Full Text] [Related]
2. Cytokeratin 7 and 20 expression in intestinal metaplasia of the distal oesophagus: relationship to gastro-oesophageal reflux disease.
Shearer C; Going J; Neilson L; Mackay C; Stuart RC
Histopathology; 2005 Sep; 47(3):268-75. PubMed ID: 16115227
[TBL] [Abstract][Full Text] [Related]
3. Cytokeratin and DAS-1 immunostaining reveal similarities among cardiac mucosa, CIM, and Barrett's esophagus.
DeMeester SR; Wickramasinghe KS; Lord RV; Friedman A; Balaji NS; Chandrasoma PT; Hagen JA; Peters JH; DeMeester TR
Am J Gastroenterol; 2002 Oct; 97(10):2514-23. PubMed ID: 12385432
[TBL] [Abstract][Full Text] [Related]
4. Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett's esophagus.
Ormsby AH; Vaezi MF; Richter JE; Goldblum JR; Rice TW; Falk GW; Gramlich TL
Gastroenterology; 2000 Sep; 119(3):683-90. PubMed ID: 10982762
[TBL] [Abstract][Full Text] [Related]
5. [Cytokeratin immunoreactivity patterns in the diagnosis of Barrett's esophagus].
Wang R; Xie J; Shen Y; Ren T
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Dec; 32(12):1820-3. PubMed ID: 23268419
[TBL] [Abstract][Full Text] [Related]
6. Utilization of cytokeratins 7 and 20 does not differentiate between Barrett's esophagus and gastric cardiac intestinal metaplasia.
Mohammed IA; Streutker CJ; Riddell RH
Mod Pathol; 2002 Jun; 15(6):611-6. PubMed ID: 12065774
[TBL] [Abstract][Full Text] [Related]
7. Etiology of intestinal metaplasia at the gastroesophageal junction.
Balaji NS; DeMeester SR; Wickramasinghe KS; Hagen JA; Peters JH; DeMeester TR
Surg Endosc; 2003 Jan; 17(1):43-8. PubMed ID: 12364989
[TBL] [Abstract][Full Text] [Related]
8. Does Cytokeratin7/20 immunoreactivity help to distinguish Barrett's esophagus from gastric intestinal metaplasia? Results of a prospective study of 75 patients.
Schilling D; Spiethoff A; Rosenbaum A; Hartmann D; Eickhoff A; Jakobs R; Weickert U; Rebe M; Bohrer MH; Riemann JF
Pathol Res Pract; 2005; 200(11-12):801-5. PubMed ID: 15792123
[TBL] [Abstract][Full Text] [Related]
9. The association of short segment Barrett's esophagus with intestinal metaplasia in stomach.
Tuncer I; Ugraş S; Uygan I; Türkdoğan K; Kösem M
Turk J Gastroenterol; 2003 Mar; 14(1):33-8. PubMed ID: 14593535
[TBL] [Abstract][Full Text] [Related]
10. Cytokeratin subsets for distinguishing Barrett's esophagus from intestinal metaplasia in the cardia using endoscopic biopsy specimens.
El-Zimaity HM; Graham DY
Am J Gastroenterol; 2001 May; 96(5):1378-82. PubMed ID: 11374671
[TBL] [Abstract][Full Text] [Related]
11. Helicobacter pylori infection, not gastroesophageal reflux, is the major cause of inflammation and intestinal metaplasia of gastric cardiac mucosa.
Goldblum JR; Richter JE; Vaezi M; Falk GW; Rice TW; Peek RM
Am J Gastroenterol; 2002 Feb; 97(2):302-11. PubMed ID: 11866266
[TBL] [Abstract][Full Text] [Related]
12. The prevalence of Helicobacter pylori infection and the status of gastric acid secretion in patients with Barrett's esophagus in Japan.
Abe Y; Ohara S; Koike T; Sekine H; Iijima K; Kawamura M; Imatani A; Kato K; Shimosegawa T
Am J Gastroenterol; 2004 Jul; 99(7):1213-21. PubMed ID: 15233656
[TBL] [Abstract][Full Text] [Related]
13. Colonization with cagA-positive Helicobacter pylori strains in intestinal metaplasia of the esophagus and the esophagogastric junction.
Ackermark P; Kuipers EJ; Wolf C; Breumelhof R; Seldenrijk CA; Timmer R; Segeren KC; Kusters JG; Smout AJ
Am J Gastroenterol; 2003 Aug; 98(8):1719-24. PubMed ID: 12907324
[TBL] [Abstract][Full Text] [Related]
14. Short segment Barrett's esophagus: clinical and histological features, associated endoscopic findings, and association with gastric intestinal metaplasia.
Weston AP; Krmpotich P; Makdisi WF; Cherian R; Dixon A; McGregor DH; Banerjee SK
Am J Gastroenterol; 1996 May; 91(5):981-6. PubMed ID: 8633592
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of cytokeratin immunoreactivity pattern for distinction of Barrett's esophagus from intestinal metaplasia of the stomach.
Iwata T; Kurita N; Nishioka M; Hidenori M; Wakatsuki S; Sano T; Shimada M
Hepatogastroenterology; 2007 Sep; 54(78):1710-2. PubMed ID: 18019700
[TBL] [Abstract][Full Text] [Related]
16. Changing pattern of cytokeratin 7 and 20 expression from normal epithelium to intestinal metaplasia of the gastric mucosa and gastroesophageal junction.
Jovanovic I; Tzardi M; Mouzas IA; Micev M; Pesko P; Milosavljevic T; Zois M; Sganzos M; Delides G; Kanavaros P
Histol Histopathol; 2002 Apr; 17(2):445-54. PubMed ID: 11962749
[TBL] [Abstract][Full Text] [Related]
17. CagA-positive strains of Helicobacter pylori may protect against Barrett's esophagus.
Vaezi MF; Falk GW; Peek RM; Vicari JJ; Goldblum JR; Perez-Perez GI; Rice TW; Blaser MJ; Richter JE
Am J Gastroenterol; 2000 Sep; 95(9):2206-11. PubMed ID: 11007219
[TBL] [Abstract][Full Text] [Related]
18. Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology.
Couvelard A; Cauvin JM; Goldfain D; Rotenberg A; Robaszkiewicz M; Fléjou JF;
Gut; 2001 Dec; 49(6):761-6. PubMed ID: 11709508
[TBL] [Abstract][Full Text] [Related]
19. Distinction between short-segment Barrett's esophageal and cardiac intestinal metaplasia.
Liu GS; Gong J; Cheng P; Zhang J; Chang Y; Qiang L
World J Gastroenterol; 2005 Oct; 11(40):6360-5. PubMed ID: 16419166
[TBL] [Abstract][Full Text] [Related]
20. Non-biopsy detection of intestinal metaplasia and dysplasia in Barrett's esophagus: a prospective multicenter study.
Sharma P; Marcon N; Wani S; Bansal A; Mathur S; Sampliner R; Lightdale C
Endoscopy; 2006 Dec; 38(12):1206-12. PubMed ID: 17163320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]